Comparative Pharmacology
Head-to-head clinical analysis: DEPO MEDROL versus LIQUID PRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPO MEDROL versus LIQUID PRED.
DEPO-MEDROL vs LIQUID PRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
5-60 mg/day orally in divided doses; typical starting dose 5-10 mg every 6-12 hours.
None Documented
None Documented
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
2.1–3.5 hours (terminal elimination half-life; shorter half-life in children; prolonged in hepatic impairment).
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Primarily renal: prednisolone is excreted as glucuronide and sulfate conjugates; less than 1% unchanged. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid